https://rta408inhibitor.com/th....orough-examination-u
Methods Data from Korean clients when you look at the stage III, placebo-controlled, randomised FANTASY (MEA112997/NCT01000506) and MENSA (MEA115588/ NCT01691521) researches were included. Customers ≥ 12 years of age with severe eosinophilic asthma received mepolizumab (FANTASY 75, 250 or 750 mg intravenously [IV]; MENSA 75 mg IV or 100 mg subcutaneously [SC]), or placebo every 4 weeks for 52 weeks (DREAM) or 32 weeks (MENSA). The principal outcome ended up being the rate of clinical
Like
Comment
Share
